Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Merck

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com

Former Merck CEO Ken Frazier on the responsibility of CEOs to uphold principles despite politics

Plus: Frazier talks about the shareholders who trusted his vision enough to support him in his early days at the helm.

Fortune

The 3 Best Dow Jones Stocks to Invest in Now, According to Wall Street

Analysts are bullish on these three dividend-paying Dow stocks, with consensus "Strong Buy" ratings and more upside expected for this diverse set of blue chips.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Ex-Merck CEO Ken Frazier says CEOs must uphold American values

Frazier was one of the first CEOs to publicly distance himself from President Donald Trump.

Fortune

COVID-19 treatments to enter the market with a hefty price tag

The COVID-19 treatments millions of have taken for free from the federal government will enter the private market next week with a hefty price tag

The Independent UK

Here's How Merck's Heavyweight Cancer Drug Helped Deliver Another Beat-And-Raise Quarter

Merck's Keytruda continued to pull its weight in the third quarter, helping deliver a beat and raise that could stoked Merck shares.

Investors Business Daily

Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks

Almost 68% of patients responded to an experimental bladder cancer treatment from Merck and Seagen. Merck stock jumped Monday.

Investors Business Daily

Dow Jones Slumps 287 Points, Weighed Down By American Express; Tesla Violates Key Level

The Dow Jones fell sharply with the other major stock indexes ahead of a busy week of high-profile earnings reports in the tech sector.

Investors Business Daily

3 Beaten-Down Dow Stocks to Buy in October

Dow Jones industrials, such as Nike, have pulled back significantly amid recent market turmoil, and now trade at a steep discount to consensus price target estimates.

Barchart

Teva Leans Into Sanofi's 'Pipeline-In-A-Product' Expertise In $1.5 Billion Deal

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

Investors Business Daily

All in: Drugmakers say yes, they'll negotiate with Medicare on price, so reluctantly

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

WEKU

Former Merck boss Ken Frazier wants CEOs to speak out

In a politicized world, the former Merck boss says CEOs should stand up and speak out. “Pick your spots.”

Fortune

How To Buy MRK For A 5% Discount, Or Achieve An 13% Annual Return

Yesterday, with Merck trading at $103.94, the November put option with a strike price of $100 was trading around $1.78. Traders selling this put would receive $178 in option premium.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Salon

Amy Klobuchar on Biden's biggest win

Minnesota senator and anti-monopoly crusader explains how fixing Medicare's drug problem will help everybody

Investors Business Daily

Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer

A bladder cancer treatment combo tied to a quartet of companies — including Seagen — succeeded in a study on Friday, leading SGEN stock to surge.

Fortune

Managers say they support skills-based hiring. But many jobs still require 4-year degrees

Just over half of hiring managers say removing four-year degree requirements would positively impact their company's hiring practices, according to a OneTen report.

Investors Business Daily

Dow Jones Falls On Weak China Data; Oil Prices Jump On Extended Production Cuts

The Dow Jones dropped Tuesday amid weak economic data out of China. Tesla stock is in focus after strong monthly China sales.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Rallies 250 Points On Unemployment Rate Jump; Tesla Stock Skids After New Model 3 Release

The Dow Jones rallied 250 points Friday on a jump in the unemployment rate. Tesla stock fell after the company released an updated Model 3 sedan.

Investors Business Daily

Dow Jones Rallies 175 Points After Key Inflation Data; Palantir Dives On Downgrade

The Dow Jones Industrial Average rose 175 points Thursday after key inflation data. Palantir Technologies dived on an analyst downgrade.

Investors Business Daily

Dow Jones Erases Gains After Weak Jobs, GDP Data; Tesla Stock Slides On Sell Rating

The Dow Jones erased early gains Wednesday on weak jobs and GDP data. Tesla stock slid after Guggenheim kept its sell rating on the EV giant.

The Guardian - US

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

Fortune

Biden targets diabetes drug Jardiance, blood thinner Eliquis, and 8 others for controversial Medicare price talks. But any relief is still years away

The move is expected to cut costs in a few years for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers.

Chicago Sun-Times

Biden targets Jardiance, Eliquis and 8 other prescription drugs for Medicare price talks

President Joe Biden says for many Americans the cost of one drug can be “the difference between life and death” as his administration announces the first drugs that’ll be targeted for price negotiations in an effort to cut Medicare costs.

Investors Business Daily

The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.